ArticleTranslational vision science & technology2025
Metabolic Biomarkers Mediate Allergic Conjunctivitis via Circulating Inflammatory Proteins: Evidence From a Mendelian Randomization Study.
Article in Translational vision science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Serum S100A12 in the clinical diagnosis of sepsis-induced myocardial dysfunction: an integrated bioinformatics and clinical data analysis.Frontiers in cardiovascular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to investigate the mediating role of metabolic biomarkers (MBs) in the association between circulating inflammatory proteins (CIPs) and allergic conjunctivitis (AC) and identify potential therapeutic targets. Methods: A Mendelian randomization (MR) study was conducted, leveraging genetic variants as instrumental variables to infer causal relationships. Data were obtained from genome-wide association studies (GWASs), and a two-sample MR was employed to estimate the direct and indirect effects of CIPs on AC through MBs. Inverse-variance weighting (IVW) served as the primary analysis method, supplemented by sensitivity analyses to assess the robustness of findings. Results: Six CIPs were found to have significant causal effects on AC. Natural killer cell receptor 2B4 (CD244) exhibited a protective effect, and interleukin-18 receptor 1 (IL-18R1), IL-6, leukemia inhibitory factor (LIF), protein S100-A12 (EN-RAGE), and TNF-related activation-induced cytokine (TRANCE) were identified as risk factors. The MR analysis indicated the mediation role of specific MBs in these associations, with MBs such as 4-oxo-retinoic acid, gulonate, 3-(4-hydroxyphenyl) lactate, S-adenosylhomocysteine, and sphingomyelin, significantly influencing the pathway from CIPs to AC. Conclusions: This study highlights the crucial role of MBs in mediating the association between CIPs and AC. These findings offer new insights into the pathophysiology of AC and suggest potential metabolic targets for novel therapeutic approaches. Translational Relevance: This study underscores the potential for targeting specific MBs as novel therapeutic approaches to modulate the inflammatory pathways implicated in AC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.